Abstract
Recurrent ovarian clear cell carcinoma (OCCC) has an abysmal prognosis with only 6∼8% ORR in chemotherapy. Antiangiogenic therapy and immunotherapy might have potential efficacy in OCCC due to the unique clinicopathological characteristics, gene expression profile, and immune microenvironment. Moreover, anti-PD-1 + Bev has shown certain efficacy in renal clear cell carcinoma, which exhibits similar gene expression profiles to OCCC. Herein, we aim to investigate the potential benefit of Sintilimab (PD-1 antibody) + Bev combination therapy for recurrent/persistent OCCC patients.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call